FcRn Inhibitor Therapies in Neurologic Diseases.
- Published in:
- CNS Drugs, 2024, v. 38, n. 6, p. 425, doi. 10.1007/s40263-024-01090-3
- By:
- Publication type:
- Article
Works matching IS 11727047 AND DT 2024 AND VI 38 AND IP 6
Results: 6
1
2
Sex Differences in Adverse Effects of Antiseizure Medications in Adults with Epilepsy: A Systematic Review.
- Published in:
- CNS Drugs, 2024, v. 38, n. 6, p. 409, doi. 10.1007/s40263-024-01088-x
- By:
- Publication type:
- Article
3
Impulse Control Disorders in Parkinson's Disease: An Overview of Risk Factors, Pathogenesis and Pharmacological Management.
- Published in:
- CNS Drugs, 2024, v. 38, n. 6, p. 443, doi. 10.1007/s40263-024-01087-y
- By:
- Publication type:
- Article
4
Synergism of Anti-CGRP Monoclonal Antibodies and OnabotulinumtoxinA in the Treatment of Chronic Migraine: A Real-World Retrospective Chart Review.
- Published in:
- CNS Drugs, 2024, v. 38, n. 6, p. 481, doi. 10.1007/s40263-024-01086-z
- By:
- Publication type:
- Article
5
Post-COVID Trajectory of Pentraxin 3 Plasma Levels Over 6 Months and Their Association with the Risk of Developing Post-Acute Depression and Anxiety.
- Published in:
- CNS Drugs, 2024, v. 38, n. 6, p. 459, doi. 10.1007/s40263-024-01081-4
- By:
- Publication type:
- Article
6
Rapid Metabolism Underlying Subtherapeutic Serum Levels of Atypical Antipsychotics Preceding Clozapine Treatment: A Retrospective Analysis of Real-World Data.
- Published in:
- CNS Drugs, 2024, v. 38, n. 6, p. 473, doi. 10.1007/s40263-024-01079-y
- By:
- Publication type:
- Article